Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert J Ossenkoppele

Showing results (101-110 of 193) with videos related to

Pageof 20
Sort By:
Nature Reviews. Clinical Oncology|September 6, 2012
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approachJan J Cornelissen, Alois Gratwohl, Richard F Schlenk, et al.
Blood|October 28, 2006
Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cellsAbdulbaqi Al-toma, Otto J Visser, Hyacintha M van Roessel, et al.
Cancer Immunology, Immunotherapy : CII|September 8, 2010
Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexesMarvin M van Luijn, Martine E D Chamuleau, Maaike E Ressing, et al.
Haematologica|October 13, 2005
Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalitiesHanneke M van der Straaten, Anja van Biezen, Ronald Brand, et al.
Blood Advances|September 16, 2020
Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantationBurak Kalin, Yvette van Norden, Michel van Gelder, et al.
Blood Advances|August 27, 2021
Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classificationInge van der Werf, Anna Wojtuszkiewicz, Manja Meggendorfer, et al.
Blood|January 14, 2014
Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitorsMichael Bots, Inge Verbrugge, Benjamin P Martin, et al.
Cancer Immunology, Immunotherapy : CII|July 25, 2018
A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemiaArjan A van de Loosdrecht, Sandra van Wetering, Saskia J A M Santegoets, et al.
Plos One|May 8, 2012
Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cellsMarvin M van Luijn, Arjan A van de Loosdrecht, Margit H Lampen, et al.
Oncoimmunology|June 5, 2013
Priming of PRAME- and WT1-specific CD8<sup>+</sup> T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapyWillemijn van den Ancker, Jurjen M Ruben, Theresia M Westers, et al.
Pageof 20

Showing results (101-110 of 193) with videos related to

Sort By:
Pageof 20
Nature Reviews. Clinical Oncology|September 6, 2012
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approachJan J Cornelissen, Alois Gratwohl, Richard F Schlenk, et al.
Blood|October 28, 2006
Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cellsAbdulbaqi Al-toma, Otto J Visser, Hyacintha M van Roessel, et al.
Cancer Immunology, Immunotherapy : CII|September 8, 2010
Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexesMarvin M van Luijn, Martine E D Chamuleau, Maaike E Ressing, et al.
Haematologica|October 13, 2005
Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalitiesHanneke M van der Straaten, Anja van Biezen, Ronald Brand, et al.
Blood Advances|September 16, 2020
Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantationBurak Kalin, Yvette van Norden, Michel van Gelder, et al.
Blood Advances|August 27, 2021
Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classificationInge van der Werf, Anna Wojtuszkiewicz, Manja Meggendorfer, et al.
Blood|January 14, 2014
Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitorsMichael Bots, Inge Verbrugge, Benjamin P Martin, et al.
Cancer Immunology, Immunotherapy : CII|July 25, 2018
A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemiaArjan A van de Loosdrecht, Sandra van Wetering, Saskia J A M Santegoets, et al.
Plos One|May 8, 2012
Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cellsMarvin M van Luijn, Arjan A van de Loosdrecht, Margit H Lampen, et al.
Oncoimmunology|June 5, 2013
Priming of PRAME- and WT1-specific CD8<sup>+</sup> T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapyWillemijn van den Ancker, Jurjen M Ruben, Theresia M Westers, et al.
Pageof 20